Renovaro BioSciences secures multiple U.S. patents in biomedical AI

Renovaro announced multiple U.S. patent allowances that significantly strengthen its competitive position in biomedical artificial intelligence. The new patents, including U.S. Application No. 18/058,732 for unbiased drug discovery predictions, expand Renovaro’s growing IP portfolio anchored by foundational patents U.S. No. 11,379,757 and recently awarded Application No. 18/058,752. Renovaro’s newly allowed patents include innovations titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions” and “Methods, Systems, and Frameworks for Federated Learning While Ensuring Bi-Directional Data Security”. These methods address critical pain points in biomedical AI, such as data sparsity, source heterogeneity, and lack of model transferability – paving the way for reproducible AI models in precision medicine. These filings also deepen the company’s IP foundation by addressing key bottlenecks in the biomedical AI space – specifically, the integration of heterogeneous data such as EHRs, genomics, imaging, and clinical trial results into standardized pipelines capable of producing clinically relevant, reproducible insights.